Advice

In the absence of a submission from the holder of the marketing authorisation.

darbepoetin alfa (Aranesp) SureClick is not recommended for use within NHS Scotland for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this formulation. As a result we cannot recommend its use within NHS Scotland

Download detailed advice28KB (PDF)

Download

Medicine details

Medicine name:
Darbepoetin alfa Sureclick (Aranesp)
SMC ID:
265/06
Indication:
Anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy
Pharmaceutical company
Amgen Ltd
BNF chapter
Nutrition and blood
Submission type
Non submission
Status
Superseded
Date advice published
08 May 2006
Additional notes

NICE MTA Advice: SMC Advice is superseded by National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal (MTA)